Carnosine and Carnosine-Related Antioxidants: A Review
Level 5 - mechanism / opinion, no new human data
Narrative review of biochemical mechanisms and patents without systematic methodology or original human clinical data
OpenAlex W2170565523 · doi:10.2174/0929867054864796
What was done
This narrative review summarizes published literature and international patents concerning the endogenous dipeptide carnosine (beta-alanyl-L-histidine) and its synthetic derivatives. It examines carnosine's biological distribution, physiological roles, and chemical mechanisms for detoxifying reactive species and lipid peroxidation by-products.
What was found
The abstract reports no numerical data, effect sizes, or quantitative findings. Qualitatively, carnosine is described as a skeletal muscle dipeptide with multiple biological activities, including membrane protection, proton buffering, transition metal complexation, and macrophage regulation. The authors note it acts as a selective scavenger of alpha,beta-unsaturated aldehydes such as 4-hydroxy-2-nonenal (HNE) and inhibits aldehyde-induced protein-protein and DNA-protein cross-linking associated with Alzheimer's disease, cardiovascular ischemia, and inflammatory disorders.
Why it matters
The paper outlines the biochemical rationale for targeting reactive carbonyl species and lipid peroxidation by-products using carnosine and engineered carnosine analogs in degenerative diseases.
Limits
The abstract gives no quantitative measurements, sample sizes, or formal systematic review methodology. It relies on preclinical, mechanistic, and patent descriptions without presenting clinical efficacy or pharmacokinetic data in humans.
Cited by
- supports Vladimir Gulevich discovered carnosine and carnitine in bovine muscle tissue in the late 19th century.